EzriCare Eye Drops Recall: Unveiling a Nationwide Health Crisis

The Centers for Disease Control and Prevention (CDC) recently issued a formal health advisory in response to an unprecedented outbreak of carbapenem-resistant Pseudomonas aeruginosa (CRPA), a bacterium notorious for its resistance to specific antibiotics, thereby instigating severe infections in affected individuals. This concerning development has been traced back to the utilization of EzriCare Artificial Tears Eye Drops. Following meticulous testing, the CDC identified the presence of CRPA in opened bottles of EzriCare eye drops, prompting an immediate and unequivocal recommendation that both healthcare practitioners and patients stop the usage of EzriCare Artificial Tears. The gravity of the situation is underscored by the fact that the specific strain of bacteria responsible for this outbreak, Verona Integron-mediated Metallo-β-lactamase (VIM) and Guiana-Extended Spectrum-β-Lactamase (GES)-producing carbapenem-resistant Pseudomonas aeruginosa (VIM-GES-CRPA), is a rarity in the US and has not been previously encountered by the CDC.

Explaining The Recall of EzriCare

Background Behind EzriCare’s Recall

Currently, there have been 81 reported adverse events across 18 states, encompassing eye infections, permanent vision loss, and, regrettably, fatalities. The severity of these consequences has catalyzed legal action, with lawsuits against EzriCare commencing on February 10, 2023. In response to this crisis, Global Pharma Healthcare, the distributor of EzriCare, executed a voluntary recall on February 2, 2023. This recall was instigated in concurrence with the Food and Drug Administration’s (FDA) recommendation, acknowledging a potential microbial contamination of the product. The preservative-free nature of EzriCare, coupled with its multi-dose usage, has contributed to an elevated risk of bacterial overgrowth post-opening. The recall was subsequently expanded on February 22, 2023, to encompass Delsam Pharma’s Artificial Eye Ointment, further highlighting the gravity of the situation and the necessity for immediate action.

It is worth mentioning that EzriCare is not an isolated case. In August 2023, the FDA issued a public warning concerning Dr. Berne’s MSM Drops and LightEyez MSM Eye Drops, both of which tested positive for bacterial contamination. Subsequent investigations exposed unsanitary conditions in an additional eye drop manufacturing facility, leading to the identification of various contaminated products under prominent brands such as CVS Health, Rite Aid, Target Up & Up™, and Walmart.

What is the impact of Carbapenam-Resistant Pseudomonas Aeruginosa (CRPA)?

Carbapenem-resistant Pseudomonas aeruginosa (CRPA) poses a formidable challenge due to its resistance to carbapenems, a vital group of antibiotics reserved for severe bacterial infections. When localized in the eyes, CRPA manifests conditions such as conjunctivitis, keratitis, and endophthalmitis, presenting limited treatment options owing to antibiotic resistance. Individuals experiencing symptoms of eye infection subsequent to EzriCare Artificial Tears usage are strongly encouraged to seek immediate medical attention. Post-medical intervention, engaging with Sokolove Law can offer invaluable guidance regarding legal options, ensuring that affected individuals do not forfeit the opportunity to hold manufacturers accountable for their negligence.

Is EzriCare the Only Brand with Challenegs?

Ezricare is not the only product with challenges

No, as per CDC, EzriCare is not the only case; FDA’s August 2023 earlier warning revealed bacterial contamination.